# NCT03275103 (NCT03275103)

> Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03275103
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Genentech, Inc.
- Conditions: Multiple Myeloma
- Interventions: Cevostamab; Tocilizumab
- Enrollment: 355
- Primary outcome: Percentage of Participants with Adverse Events (AEs)
- Primary outcome: Percentage of Participants With Dose-Limiting Toxicities (DLTs)
- Primary outcome: Arms E and J Only: Incidence and Severity of Cytokine-release Syndrome (CRS) Following Tocilizumab Premedication Followed by Treatment with Cevostamab

## Indexed commentary on NCT03275103 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03275103